| Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate L Bunse, S Pusch, T Bunse, F Sahm, K Sanghvi, M Friedrich, D Alansary, ... Nature medicine 24 (8), 1192-1203, 2018 | 454 | 2018 |
| Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas M Friedrich, R Sankowski, L Bunse, M Kilian, E Green, ... Nature cancer 2 (7), 723-740, 2021 | 154 | 2021 |
| Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas K Aslan, V Turco, J Blobner, JK Sonner, AR Liuzzi, NG Núñez, D De Feo, ... Nature communications 11 (1), 931, 2020 | 143 | 2020 |
| The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients MJ Friedrich, P Neri, N Kehl, J Michel, S Steiger, M Kilian, N Leblay, ... Cancer Cell 41 (4), 711-725. e6, 2023 | 92 | 2023 |
| Dysfunctional dendritic cells limit antigen-specific T cell response in glioma M Friedrich, M Hahn, J Michel, R Sankowski, M Kilian, N Kehl, M Günter, ... Neuro-oncology 25 (2), 263-276, 2023 | 49 | 2023 |
| MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors M Kilian, R Sheinin, CL Tan, M Friedrich, C Krämer, A Kaminitz, ... Cancer Cell 41 (2), 235-251. e9, 2023 | 36 | 2023 |
| T-cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas M Kilian, M Friedrich, K Sanghvi, E Green, S Pusch, D Kawauchi, M Löwer, ... Clinical Cancer Research 28 (2), 378-389, 2022 | 14 | 2022 |
| Genetically modified cellular therapies for malignant gliomas M Kilian, T Bunse, W Wick, M Platten, L Bunse International Journal of Molecular Sciences 22 (23), 12810, 2021 | 11 | 2021 |
| Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes J Blobner, M Kilian, CL Tan, K Aslan, K Sanghvi, J Meyer, M Fischer, ... Neuro-oncology advances 3 (1), vdab147, 2021 | 7 | 2021 |
| IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells N Kehl, M Kilian, J Michel, TR Wagner, S Uhrig, A Brobeil, LS Sester, ... Journal for Immunotherapy of Cancer 10 (10), 2022 | 6 | 2022 |
| T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells KHN Lu, J Michel, M Kilian, K Aslan, H Qi, N Kehl, S Jung, K Sanghvi, ... Neuro-oncology advances 4 (1), vdac140, 2022 | 5 | 2022 |
| Tumor-reactive T helper cells in the context of vaccination against glioma B Zhao, M Kilian, T Bunse, M Platten, L Bunse Cancer cell 41 (11), 1829-1834, 2023 | 4 | 2023 |
| NLGN4X TCR transgenic T cells to treat gliomas C Krämer, M Kilian, YC Chih, A Kourtesakis, DC Hoffmann, T Boschert, ... Neuro-oncology 26 (2), 266-278, 2024 | 3 | 2024 |
| In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma J Hunger, K Schregel, B Boztepe, DA Agardy, V Turco, K Karimian-Jazi, ... Theranostics 13 (15), 5170, 2023 | 3 | 2023 |
| Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3. 1) enhances dendritic cell vaccination in experimental melanoma XW Zhang, K Huck, K Jähne, F Cichon, JK Sonner, F Ufer, S Bauer, ... Oncoimmunology 10 (1), 1920739, 2021 | 3 | 2021 |
| Imprinted and ancient gene: a potential mediator of cancer cell survival during tryptophan deprivation P Tomek, SK Gore, CL Potts, CG Print, MA Black, A Hallermayr, M Kilian, ... Cell communication and signaling 16, 1-15, 2018 | 3 | 2018 |
| The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance M Kilian, MJ Friedrich, KHN Lu, D Vonhören, S Jansky, J Michel, A Keib, ... Science Immunology 9 (95), eadj7970, 2024 | 2 | 2024 |
| OAB-002: The preexisting T cell landscape determines response to T cell-engagers therapy in multiple myeloma M Friedrich, N Kehl, P Neri, J Michel, N Leblay, R Maity, M Kilian, H Lee, ... Clinical Lymphoma Myeloma and Leukemia 22, S1-S2, 2022 | 1 | 2022 |
| EXTH-28. NLGN4X TCR transgenic T cells targeting experimental gliomas C Krämer, M Kilian, R Will, K Sanghvi, E Green, M Friedrich, W Wick, ... Neuro-oncology 23 (Suppl 6), vi169, 2021 | 1 | 2021 |
| Transgenic T cell therapy targeting the glioblastoma stem cell antigen PTPRZ1 with a vaccine-induced, patient-derived T cell receptor L Bunse, YC Chih, AC Dietsch, P Koopmann, X Ma, DA Agardy, B Zhao, ... | | 2024 |
